Skip to main content
Clinical Trials/NCT04242212
NCT04242212
Unknown
Not Applicable

A Prospective, Comparative Study of Clinical Outcomes Following Clinic-based Versus Self-use of Medication Abortion Using a Misoprostol-only Regimen

Ipas1 site in 1 country4,000 target enrollmentMay 19, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Induced Abortion
Sponsor
Ipas
Enrollment
4000
Locations
1
Primary Endpoint
Need for additional treatment to complete abortion
Last Updated
6 years ago

Overview

Brief Summary

The goal of the study is to determine whether important clinical outcomes differ among women who access a misoprostol-only medication abortion regimen from a patent medicine vendor when compared with those who access it from a clinic.

Detailed Description

Medication abortion with a misoprostol-only regimen within the first 10 weeks of pregnancy is safe and effective. Investigators aim to assess whether self-use of early (\<9 weeks) medication abortion using a misoprostol-only regimen results in non-inferior rates of clinical outcomes when compared with clinic-based provision of medication abortion. The investigators will prospectively recruit women who obtain misoprostol from patent medicine vendors and clinics. Follow-up will occur by telephone during three phone calls within 45 days of the first dose of misoprostol.

Registry
clinicaltrials.gov
Start Date
May 19, 2019
End Date
June 30, 2020
Last Updated
6 years ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
Ipas
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Purchased a misoprostol-only abortion regimen at a PMV or from a clinic
  • Be at least 15 years of age
  • Have a known LMP of less than 9 weeks
  • No contraindications to medical abortion
  • Willing and able to give informed consent
  • Have a mobile phone of which they are the independent user or be willing to be followed-up in person
  • Willing to be contacted with questions about her abortion by telephone at 1-3, 10-29 and 30-45 days following initial contact.

Exclusion Criteria

  • Contraindications to misoprostol
  • Age \<15 or \>49

Outcomes

Primary Outcomes

Need for additional treatment to complete abortion

Time Frame: Final assessment at 45 days following misoprostol

The primary outcome of the study will be the need for additional treatment to complete the abortion (either aspiration or repeated misoprostol \>3 doses) following a woman taking the medication abortion pills.

Secondary Outcomes

  • Serious complications/ morbidity(Final assessment at 45 days following misoprostol)

Study Sites (1)

Loading locations...

Similar Trials